Bicara Therapeutics Quote - BCAX

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

13.25

Bid

11.31

Ask

15.60

Volume

488,271

12.51 Day's Range 13.38

11.10 52 Week Range 27.95

Market Cap

721.007M

Previous Close

12.91

Open

12.88

Last Trade

200

13.25

(formt)

Last Trade Time

Financial Volume

US$ 6,299,482

VWAP

12.9016

Average Volume (3m)

446,328

Shares Outstanding

54,415,619

Dividend Yield

PE Ratio

-13.22

Earnings Per Share (EPS)

-0.96

Revenue

Net Profit

-51.99M

Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor... Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, or HNSCC, where there remains a significant unmet need. We intend to initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy in recurrent/metastatic HNSCC excluding HPV-positive patients with oropharyngeal squamous cell carcinoma late in the fourth quarter of 2024 or early in the first quarter of 2025. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.bicara.com

Headquarters

Wilmington, Delaware, USA

Founded

Bicara Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BCAX. The last closing price for Bicara Therapeutics was US$12.91. Over the last year, Bicara Therapeutics shares have traded in a share price range of US$ 11.10 to US$ 27.95.

Bicara Therapeutics currently has 54,415,619 shares outstanding. The market capitalization of Bicara Therapeutics is US$702.51 million. Bicara Therapeutics has a price to earnings ratio (PE ratio) of -13.22.

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium

BOSTON, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds...

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for...

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for...

Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	1.22	10.1413133832	12.03	13.25	11.1	448573	12.08590356	CS
4	-3.64	-21.5512137359	16.89	17.39	11.1	400328	13.16687508	CS
12	-10.34	-43.8321322594	23.59	24.7	11.1	446328	17.0426399	CS
26	-13	-49.5238095238	26.25	27.95	11.1	432004	19.50205686	CS
52	-13	-49.5238095238	26.25	27.95	11.1	432004	19.50205686	CS
156	-13	-49.5238095238	26.25	27.95	11.1	432004	19.50205686	CS
260	-13	-49.5238095238	26.25	27.95	11.1	432004	19.50205686	CS

BCAX - Frequently Asked Questions (FAQ)

What is the current Bicara Therapeutics share price?

The current share price of Bicara Therapeutics is US$ 13.25

How many Bicara Therapeutics shares are in issue?

Bicara Therapeutics has 54,415,619 shares in issue

What is the market cap of Bicara Therapeutics?

The market capitalisation of Bicara Therapeutics is USD 702.51M

What is the 1 year trading range for Bicara Therapeutics share price?

Bicara Therapeutics has traded in the range of US$ 11.10 to US$ 27.95 during the past year

What is the PE ratio of Bicara Therapeutics?

The price to earnings ratio of Bicara Therapeutics is -13.22

What is the reporting currency for Bicara Therapeutics?

Bicara Therapeutics reports financial results in USD

What is the latest annual profit for Bicara Therapeutics?

The latest annual profit of Bicara Therapeutics is USD -51.99M

What is the registered address of Bicara Therapeutics?

The registered address for Bicara Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801

What is the Bicara Therapeutics website address?

The website address for Bicara Therapeutics is www.bicara.com

Which industry sector does Bicara Therapeutics operate in?

Bicara Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TCTMTCTM Kids IT Education Inc	US$ 0.764 (321.87%)	729.72M
REBNReborn Coffee Inc	US$ 3.31 (63.05%)	55.54M
FCUVFocus Universal Inc	US$ 5.87 (56.62%)	1.73M
SOPASociety Pass Inc	US$ 1.54 (56.50%)	13.82M
CYCNCyclerion Therapeutics Inc	US$ 3.92 (54.33%)	82.39M
ENVBEnveric Biosciences Inc	US$ 2.0899 (-46.41%)	1.57M
NIVFNewGenIvf Group Ltd	US$ 0.1489 (-42.51%)	14.8M
GLSTGlobal Star Acquisition Inc	US$ 8.83 (-39.10%)	23.89k
PRPHProPhase Labs Inc	US$ 0.2633 (-38.02%)	872.46k
SPGCSacks Parente Golf Inc	US$ 0.5601 (-37.86%)	7.27M
TCTMTCTM Kids IT Education Inc	US$ 0.764 (321.87%)	729.72M
NVDANVIDIA Corporation	US$ 120.07 (-3.67%)	388.54M
RIMEAlgorhythm Holdings Inc	US$ 0.02565 (5.12%)	338.75M
BHATBlue Hat Interactive Entertainment Technology	US$ 0.0355 (-11.25%)	236.29M
CLEUChina Liberal Education Holdings Ltd	US$ 0.1938 (30.77%)	234.8M